国产组合,刷新一线治疗UC东亚人群OS历史

瞪羚社
Oct 22

上方“瞪羚社”即刻关注并加入社群聚焦高成长公司,15万+投资菁英共同关注自Padcev+K药突破尿路上皮癌一线治疗起,ADC+IO便成为全球创新药开发的下一个趋势,但谁能想到,继“P+K”之后,全球在ADC+IO三期注册临床中再次取得突破的,是一对国产的组合。10月19日,荣昌生物一项维迪西妥单抗(RC48)联合特瑞普利单抗(PD-1)对比化疗一线治疗HER2表达局部晚期或转移性尿路上皮癌(UC)...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10